Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia.
AffiliationDepartment of Medical Oncology, Christie Hospital, Manchester, U.K.
MetadataShow full item record
AbstractA region-specific radioimmunoassay has been employed to measure levels of immunoreactive parathyroid hormone-related protein(50-69) (iPTHrP(50-69)) in patients with tumour-induced hypercalcaemia (TIH). This assay is based on an antiserum raised against synthetic human PTHrP(50-69). The assay showed no cross-reactivity with human or bovine parathyroid hormone(1-84). The effect of a single dose (60 mg) of pamidronate was studied in 25 consecutive patients with TIH. All were rehydrated prior to treatment. All but 2 patients (8%) became normocalcaemic after treatment; both of these had very high levels of iPTHrP(50-69). Time to achieve normocalcaemia, as an index of relative resistance to pamidronate, correlated positively with pretreatment level of iPTHrP(50-69). Absence of radiological evidence of bone metastases also predicted relative resistance to pamidronate. In this study, iPTHrP(50-69)-induced osteoclastic bone resorption was a more important mechanism in the causation of TIH than PTHrP-induced renal reabsorption of calcium as assessed by the renal thresholds for calcium and phosphate.
CitationParathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia. 1991, 27 (12):1629-33 Eur. J. Cancer
JournalEuropean Journal of Cancer
- Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.
- Authors: Gurney H, Grill V, Martin TJ
- Issue date: 1993 Jun 26
- Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
- Authors: Walls J, Ratcliffe WA, Howell A, Bundred NJ
- Issue date: 1994 Jul
- Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
- Authors: Body JJ, Dumon JC
- Issue date: 1994 Apr
- Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
- Authors: Fraser WD, Logue FC, Gallacher SJ, O'Reilly DS, Beastall GH, Ralston SH, Boyle IT
- Issue date: 1991 Feb
- Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia.
- Authors: Nesković-Konstantinović Z, Mitrović L, Petrović J, Stamatović L, Ristović Z
- Issue date: 1995 Nov